Patents by Inventor Markus Hossbach

Markus Hossbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260053941
    Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., an RNAi oligonucleotide such as an siRNA, useful for targeting DUX4) covalently linked to an antibody (e.g., anti-TfR1 antibody).
    Type: Application
    Filed: November 7, 2025
    Publication date: February 26, 2026
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Timothy Weeden, Nelson Hsia, Stefano Zanotti, Oxana Beskrovnaya, Qifeng Qiu, Scott Hilderbrand, Jochen Deckert, Hans-Peter Vornlocher, Markus Hossbach, Kathrin Hultsch, Nicholas C. Yoder, Benjamin Vieira
  • Publication number: 20260002157
    Abstract: Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
    Type: Application
    Filed: September 9, 2025
    Publication date: January 1, 2026
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Patent number: 12454691
    Abstract: Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: October 28, 2025
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Publication number: 20250146000
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: September 13, 2024
    Publication date: May 8, 2025
    Inventors: Dinah Wen-Yee SAH, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Publication number: 20240415868
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the HTT gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating Huntington's Disease (HD) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: February 29, 2024
    Publication date: December 19, 2024
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Pengcheng Zhou, Xin Wang, Jochen Deckert, Markus Hossbach
  • Patent number: 12129469
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: October 29, 2024
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Patent number: 12123002
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: October 22, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Publication number: 20240226203
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Application
    Filed: July 13, 2023
    Publication date: July 11, 2024
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • Publication number: 20240131093
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Application
    Filed: July 12, 2023
    Publication date: April 25, 2024
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • Patent number: 11965163
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: April 23, 2024
    Assignee: MiNA Therapeutics Limited
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • Patent number: 11951121
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the HTT gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating Huntington's Disease (HD) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 9, 2024
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Pengcheng Zhou, Xin Wang, Jochen Deckert, Markus Hossbach
  • Patent number: 11920134
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 5, 2024
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John Frederick Boylan, Birgit Bramlage, Markus Hossbach, John Reidhaar-Olson
  • Publication number: 20240035026
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: September 28, 2021
    Publication date: February 1, 2024
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • Publication number: 20230365970
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Application
    Filed: July 28, 2023
    Publication date: November 16, 2023
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Publication number: 20230332153
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Application
    Filed: November 29, 2022
    Publication date: October 19, 2023
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Publication number: 20230332156
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: December 20, 2022
    Publication date: October 19, 2023
    Inventors: Dinah Wen-Yee SAH, Jinzhao HOU, Mathieu E. NONNENMACHER, Pengcheng ZHOU, Markus HOSSBACH, Jochen DECKERT
  • Patent number: 11752181
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: September 12, 2023
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • Publication number: 20230159929
    Abstract: Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
    Type: Application
    Filed: September 7, 2022
    Publication date: May 25, 2023
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Patent number: 11549110
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: January 10, 2023
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Patent number: 11542506
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: January 3, 2023
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert